Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Five Prime Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897…
Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
Agios Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
BeiGene, Ltd. $800 Million Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public…
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by…
Davis Polk Advises TiGenix on Its Acquisition by Takeda
Davis Polk is advising TiGenix in connection with its entry into an offer and support agreement with Takeda Pharmaceutical…
Denali Therapeutics Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of…
Revance Therapeutics, Inc. $190 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock…
Editas Medicine, Inc. $50 Million Follow-On Offering
Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000…